Candel Therapeutics Presents Preclinical Data From Its EnLIGHTEN Discovery Platform at SITC; The First Experimental Agent Is Alpha-201-Macro1, An Investigational Viral Immunotherapy Designed To Activate Innate Immune Surveillance
Candel Therapeutics Presents Preclinical Data From Its EnLIGHTEN Discovery Platform at SITC; The First Experimental Agent Is Alpha-201-Macro1, An Investigational Viral Immunotherapy Designed To Activate Innate Immune Surveillance
Candel Therapeutics公佈了來自SITC的Enlighten發現平台的臨床前數據;第一種實驗藥物是Alpha-201-Macro1,這是一種旨在激活先天免疫監測的在研病毒免疫療法
Candel Therapeutics公佈了來自SITC的Enlighten發現平台的臨床前數據;第一種實驗藥物是Alpha-201-Macro1,這是一種旨在激活先天免疫監測的在研病毒免疫療法